SecBot SecBot
6-K ·Filed Jun 29, 2026

ABVX

Abivax S.A.
BULLISH
Impact 7/10
Horizonmonths Processed4mo ago SEC0001193125-26-288752
Notable filing: 6-K
Actionable Insight ▲ Bullish

The positive Part 2 data de-risks the obefazimod program ahead of NDA submission in Q4 2026. Traders should monitor for regulatory updates, potential partnership announcements, and the H1 2026 financial results on September 21, 2026.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$133.26
T+0 close · Jun 29, 2026 · via day close
Latest settled
−29.36%
T+60 · $94.13
Vs SPY
−32.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 30 $133.26entry
  2. T+1 · 5mo ago −0.53%α −0.39% · $132.56
  3. T+5 · 4mo ago +8.05%α +7.45% · $143.99
  4. T+20 · 4mo ago −3.95%α −2.92% · $128.00
  5. T+60 · 8w ago −29.36%α −32.18% · $94.13
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abivax reported positive topline results from Part 2 of the Phase 3 ABTECT maintenance trial for obefazimod in ulcerative colitis, showing clinically meaningful efficacy in refractory patients (37.2% clinical remission at 50 mg in induction non-responders) and a safety profile with malignancy rates within UC background ranges. The company remains on track for NDA submission in Q4 2026, strengthening the drug's regulatory path.

Key Facts

  • 50 mg obefazimod achieved 37.2% clinical remission, 61.5% clinical response, 48.0% endoscopic improvement, 44.6% HEMI, and 34.5% endoscopic remission in induction non-responders at Week 44.
  • Part 1 relapsers re-treated with 50 mg obefazimod achieved 45.0% clinical remission (placebo→50 mg) and 45.5% (25 mg→50 mg).
  • Exposure-adjusted incidence rate (EAIR) for malignancies excluding NMSC in the integrated UC program (all active) was 0.35 per 100 PY, within the UC background range of 0.30–0.70.
  • EAIR for NMSC in the integrated program (all active) was 0.59 per 100 PY, within the UC background range of 0.70–1.40.
  • No new safety signals emerged; NDA submission remains on track for Q4 2026.

Financial Impact

Positive catalyst for ABVX stock; strengthens probability of NDA approval and potential commercial launch. No financial figures provided in the filing.

probability of regulatory approvalfuture revenue potential

Risk Factors

  • Regulatory risk: FDA may require additional data or raise concerns about safety or efficacy.
  • Competition from existing and emerging UC therapies (e.g., JAK inhibitors, anti-integrins).
  • Financing risk: Abivax may need to raise capital to fund commercialization and ongoing trials.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-288752
Document: d110874dex991.htm0001193125-26-288752
Document: 0001193125-26-288752-index-headers.html0001193125-26-288752
Document: 0001193125-26-288752-index.html0001193125-26-288752
Document: 0001193125-26-288752.txt0001193125-26-288752

Track record

10 reports on ABVX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +33.05% at T+60 after the Jul 2, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $83.40 Now $83.61 +0.25% settles Nov 24
  2. Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $86.59 to $85.73 Now $83.61 −3.44% ▼ −0.99% +1.71% vs SPY
  3. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $130.00 to $121.45 Now $83.61 −35.68% ▼ −6.58% −7.79% vs SPY
  4. Jul 2, 202619w ago 6-K Bearish 6/10 Entry $144.65 to $140.74 Now $83.61 +42.20% ▲ +2.70% +3.63% vs SPY
  5. Jul 2, 202619w ago 424B5 Bearish 6/10 Entry $144.65 to $140.74 Now $83.61 +42.20% ▲ +2.70% +3.63% vs SPY
  6. Jul 1, 202619w ago Press Release Bearish 6/10 Entry $132.56 to $142.17 Now $83.61 +36.93% ▼ −7.25% −6.99% vs SPY
  7. Jun 29, 202620w ago 6-K Bullish 7/10 Viewing Entry $133.26 to $143.99 Now $83.61 −37.26% ▲ +8.05% +7.45% vs SPY
  8. Jun 29, 202620w ago Press Release Bullish 7/10 Entry $133.26 to $143.99 Now $83.61 −37.26% ▲ +8.05% +7.45% vs SPY
  9. May 22, 202625w ago Press Release Neutral 5/10 Entry $126.41 to $129.69 Now $83.61 −33.86% ▲ +2.59% +1.51% vs SPY
  10. Mar 23, 202634w ago Press Release Mixed 6/10 Entry $110.17 to $111.35 Now $83.61 −24.11% ▲ +1.07% +1.49% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens Wed (11h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026